Is HGH (somatropin) approved or legal?

Somatropin is an FDA-approved prescription drug for specific conditions such as pediatric and adult growth-hormone deficiency, Turner and Prader-Willi syndromes, short bowel syndrome, and HIV wasting. It is not approved for anti-aging or performance, distributing it for those purposes is illegal in the US, and it is banned in sport by WADA at all times. Gray-market products are sold for research use only.

How is HGH dosed, and is it measured in IU or mg?

It is measured in both: roughly 3 IU per milligram. Clinical adult replacement is typically about 0.15-0.30 mg/day subcutaneously, titrated by serum IGF-1; pediatric dosing is weight-based. Anecdotal off-label community figures (1-4 IU/day for wellness, 4-10+ IU/day for performance) are not validated regimens and carry higher risk. This is reference information, not dosing advice.

Does HGH actually work for anti-aging or building muscle?

For diagnosed GH deficiency it clearly works. For anti-aging and athletic performance the evidence is weak: the main systematic review in healthy older adults found only small body-composition changes and more side effects, and ergogenic effects are largely unproven. The risk-benefit balance off-label is unfavorable.

What is HGH's half-life?

After subcutaneous injection the apparent half-life is roughly 3-3.4 hours; intravenously it is much shorter (about 20-36 minutes). Its downstream signal, IGF-1, persists far longer, which is why clinical dosing is monitored by IGF-1 levels.

At replacement doses in deficient patients it has a well-characterized safety profile. Common dose-dependent effects include fluid retention, joint pain, carpal tunnel syndrome, and impaired glucose tolerance; supraphysiologic dosing risks acromegalic changes, and GH is contraindicated in active cancer. It should be used only under medical supervision; non-prescribed use is both unsafe and illegal for enhancement.

Hormonal

HGH

Also known as: Somatropin, Recombinant Human Growth Hormone, rhGH, Growth Hormone, GH

Recombinant human growth hormone (somatropin), an FDA-approved 191-amino-acid hormone for defined deficiency states; widely diverted off-label for anti-aging and performance...

Last updated July 11, 2026

Buy HGH

Overview

HGH refers to human growth hormone. In the research-peptide and performance markets it almost always means somatropin - recombinant human growth hormone (rhGH), a 191-amino-acid single-chain polypeptide produced by recombinant DNA technology and identical in sequence to the GH made by the pituitary. Its potency is expressed in both mass and International Units; the current conversion is roughly 3 IU per milligram (so 1 mg is about 3 IU, with older preparations near 2.6-3 IU/mg). It is marketed as approved medicines such as Genotropin, Norditropin, Humatrope, Saizen, and Omnitrope. Unlike most compounds catalogued here, somatropin is an approved drug with a mature clinical evidence base for specific indications: pediatric and adult growth-hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age children who fail to catch up, short bowel syndrome, and HIV-associated wasting, among others. For these uses it is supported by randomized trials and long-term surveillance. The contrast is the off-label market. GH is widely diverted for anti-aging and athletic or bodybuilding performance, neither of which is FDA-approved. The landmark evidence on healthy older adults found only small changes in body composition alongside more adverse events, and US law specifically prohibits distributing GH for anti-aging or enhancement. GH is also prohibited in sport by WADA at all times. Material sold outside the approved supply chain is labeled for research use only and may be impure or counterfeit. This entry summarizes the published science and community-reported practice for reference only. It is not medical advice and does not endorse non-prescribed human use.

How it works

Growth hormone binds the growth-hormone receptor (GHR), a class I cytokine receptor. Binding reorients a pre-formed receptor dimer and activates the receptor-associated tyrosine kinase JAK2. JAK2 then phosphorylates the receptor and recruits STAT5 (chiefly STAT5b), which dimerizes, enters the nucleus, and drives transcription - most importantly of insulin-like growth factor 1 (IGF-1). IGF-1, produced mainly in the liver (endocrine) and locally in peripheral tissues (autocrine/paracrine), mediates most of GH's anabolic and growth-promoting effects. GH also exerts direct, IGF-1-independent metabolic actions: it stimulates lipolysis (fat breakdown) and is counter-regulatory to insulin, promoting insulin resistance at higher exposures. Clinical replacement is therefore titrated to keep serum IGF-1 within an age-appropriate range.

Researched effects

Clinical Restores growth and corrects metabolic deficits in diagnosed GH deficiency (pediatric and adult)
Clinical Increases linear growth in approved conditions such as Turner syndrome, Prader-Willi syndrome, and small-for-gestational-age short stature
Clinical Improves lean body mass and reduces fat mass; supports treatment of HIV-associated wasting and short bowel syndrome
Clinical Produces small body-composition changes (more lean mass, less fat) in healthy older adults
Anecdotal Improves athletic performance / muscle gain in trained athletes
Anecdotal Reverses aging, improves skin, sleep, and vitality with off-label use

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

Established and approved. Adult GH-deficiency replacement is typically about 0.15-0.30 mg/day subcutaneously to start, titrated by serum IGF-1 (with lower starting doses for older, obese, or diabetic patients, up to roughly 1.33 mg/day maximum on some labels). Pediatric GH deficiency is weight-based, on the order of 0.16-0.24 mg/kg/week subcutaneously, with higher ranges for indications such as Turner syndrome and Prader-Willi. Dosing is individualized and IGF-1-guided under medical supervision.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction, and note that non-prescribed use of GH for anti-aging or performance is illegal in the US. Community/harm-reduction sources commonly report 1-4 IU/day for so-called wellness or anti-aging use and 4-10+ IU/day for performance enhancement, in cycles of about 3-6 months or longer. These are forum-consensus figures, not validated or peer-reviewed regimens, and the higher (supraphysiologic) ranges drive most of the side-effect and acromegaly risk described below.

Half-life: Route-dependent. After subcutaneous injection the apparent elimination half-life is roughly 3-3.4 hours (slow absorption from the depot prolongs it), with subcutaneous bioavailability around 70-90%. After intravenous dosing the half-life is much shorter, roughly 20-36 minutes. GH is cleared by protein catabolism in the liver and kidney.
Routes: subcutaneous, intramuscular

Safety & side effects

Dose-dependent adverse effects are well documented and include fluid/water retention, peripheral edema, joint and muscle pain (arthralgia/myalgia), carpal tunnel syndrome, and impaired glucose tolerance / insulin resistance; most ease with dose reduction. Chronic supraphysiologic dosing can produce acromegalic changes and risks long-term harm. GH raises IGF-1, and high circulating IGF-1 has epidemiologic associations with some cancers; large surveillance data suggest replacement-dose GH in deficient patients does not raise cancer risk above baseline, but GH is contraindicated in active malignancy. Other contraindications include acute critical illness, active proliferative diabetic retinopathy, and severe obesity or respiratory impairment in Prader-Willi syndrome. GH is prohibited in sport by WADA at all times (category S2), and non-prescribed distribution for anti-aging or enhancement is illegal in the US. Counterfeit and underdosed product is a real risk in the gray market. This information is for research reference only and is not a recommendation for non-prescribed human use.

Research summary

The evidence on GH is unusually bifurcated. For its approved indications - pediatric and adult GH deficiency, Turner and Prader-Willi syndromes, small-for-gestational-age short stature, short bowel syndrome, and HIV wasting - the literature is mature, with randomized trials and large long-term safety registries (one overview covering more than 15,000 GH-treated adults). In appropriately selected, GH-deficient patients, replacement reliably improves growth, body composition, and metabolic parameters with a well-characterized safety profile. The off-label story is much weaker. The frequently cited 2007 Annals of Internal Medicine systematic review of GH in the healthy elderly found only small body-composition changes accompanied by higher rates of edema, joint pain, carpal tunnel symptoms, and glucose intolerance, and concluded GH could not be recommended as anti-aging therapy; later reviews reaffirm uncertain long-term benefit. Ergogenic evidence is similarly thin, with most measurable effects in untrained subjects rather than confirmed performance gains. The honest assessment is that somatropin is a genuinely effective, approved hormone for defined deficiency states but an unproven and risk-laden choice for anti-aging or performance, where benefits are small and adverse effects are common. It should be used only under medical supervision for approved indications; non-prescribed use is both legally prohibited and poorly supported by evidence.

FAQ

Is HGH (somatropin) approved or legal?: Somatropin is an FDA-approved prescription drug for specific conditions such as pediatric and adult growth-hormone deficiency, Turner and Prader-Willi syndromes, short bowel syndrome, and HIV wasting. It is not approved for anti-aging or performance, distributing it for those purposes is illegal in the US, and it is banned in sport by WADA at all times. Gray-market products are sold for research use only.
How is HGH dosed, and is it measured in IU or mg?: It is measured in both: roughly 3 IU per milligram. Clinical adult replacement is typically about 0.15-0.30 mg/day subcutaneously, titrated by serum IGF-1; pediatric dosing is weight-based. Anecdotal off-label community figures (1-4 IU/day for wellness, 4-10+ IU/day for performance) are not validated regimens and carry higher risk. This is reference information, not dosing advice.
Does HGH actually work for anti-aging or building muscle?: For diagnosed GH deficiency it clearly works. For anti-aging and athletic performance the evidence is weak: the main systematic review in healthy older adults found only small body-composition changes and more side effects, and ergogenic effects are largely unproven. The risk-benefit balance off-label is unfavorable.
What is HGH's half-life?: After subcutaneous injection the apparent half-life is roughly 3-3.4 hours; intravenously it is much shorter (about 20-36 minutes). Its downstream signal, IGF-1, persists far longer, which is why clinical dosing is monitored by IGF-1 levels.
Is HGH safe?: At replacement doses in deficient patients it has a well-characterized safety profile. Common dose-dependent effects include fluid retention, joint pain, carpal tunnel syndrome, and impaired glucose tolerance; supraphysiologic dosing risks acromegalic changes, and GH is contraindicated in active cancer. It should be used only under medical supervision; non-prescribed use is both unsafe and illegal for enhancement.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.